Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Pulse Biosciences, Inc. : Appoints Richard van den Broek to Board of Directors

08/06/2020 | 04:10pm EDT

Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a novel bioelectric medicine company progressing Nano-Pulse StimulationTM (NPS™) technology, announced today the appointment of Richard van den Broek to its board of directors. In connection with his appointment to the board, Mr. van den Broek will also serve as a member of the audit committee and the compensation committee of the Board.

“Several of our current Board members served alongside Richard at Pharmacyclics Inc. A more able and productive Board member would be hard to find,” said Robert Duggan, Chairman of the Company’s Board of Directors. “We all look forward to reunite around the mission and vision of Pulse Biosciences.”

“Richard is a great addition to our Board because of his deep understanding of the life science sector, both in the US and globally,” added Darrin Uecker, President and Chief Executive Officer. “His experience will be a valuable asset in achieving the mission of our Company.”

Mr. van den Broek currently serves as managing partner of HSMR Advisors, LLC, a position he has held since February 2004, and as a director of PhaseBio Pharmaceuticals, Inc. since February 2019. He previously served on the boards of directors of Pharmacyclics, Inc. from December 2009 to April 2015, Response Genetics, Inc. from December 2010 to September 2015, Special Diversified Opportunities, Inc. from March 2008 to October 2015 and Celldex Therapeutics, Inc. from December 2014 to December 2016.

Mr. van den Broek received an A.B. from Harvard University and is a Chartered Financial Analyst.

About Pulse Biosciences®

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve and extend the lives of patients. If cleared, the CellFX® System will be the first commercial product to harness the distinctive advantages of the Company’s proprietary Nano-Pulse Stimulation™ technology to treat a variety of applications for which an optimal solution remains unfulfilled. Nano-Pulse Stimulation technology delivers nano-second pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue. Subject to regulatory approval, the initial commercial use of the CellFX System is expected to address a broad range of dermatologic conditions that share high demand among patients and practitioners for improved and durable aesthetic outcomes. Designed as a multi-application platform, the CellFX System is intended to offer customer value with a utilization-based revenue model across an expanding spectrum of clinical applications. To learn more, please visit www.pulsebiosciences.com.

Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

Caution: Pulse Biosciences’ CellFX System and Nano-Pulse Stimulation technology are for investigational use only.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws. These statements include, among other things, statements relating to Nano-Pulse Stimulation technology including the effectiveness of such technology, the CellFX System including the benefits of the CellFX System and commercialization of the CellFX System and the potential of Nano-Pulse Stimulation technology to treat medical needs across medical specialties, the Company’s market opportunity, and other future events. These statements are not historical facts but rather are based on Pulse Biosciences’ current expectations, estimates, and projections regarding Pulse Biosciences’ business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expects,” “intends,” “plans,” “projects,” “believes,” “estimates,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Pulse Biosciences’ control. Additionally, you should not consider past results to be an indication of our future performance. Additional risks and uncertainties relating to the proposed offering, Pulse Biosciences and its business can be found under the heading “Risk Factors” in Pulse Biosciences’ most recent periodic, quarterly and annual reports filed with the SEC and in the accompanying prospectus relating to the offering to be filed with the SEC. Pulse Biosciences undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances in the future, even if new information becomes available.

ę Business Wire 2020
06/09PULSE BIOSCIENCESá : Wins Canada Regulatory Ok for CellFX System
06/09PULSE BIOSCIENCESá : Announces Health Canada Approval for CellFX« System (Form 8..
06/09PULSE BIOSCIENCES, INC.á : Other Events, Financial Statements and Exhibits (form..
06/09PULSE BIOSCIENCESá : Announces Health Canada Approval for CellFX« System
05/24PULSE BIOSCIENCESá : to Participate in the Jefferies Healthcare Conference
05/20PULSE BIOSCIENCES, INC.á : Submission of Matters to a Vote of Security Holders (..
05/13PULSE BIOSCIENCESá : reg; Presents Clinical Study Results of Nano-Pulse Stimulat..
05/12PULSE BIOSCIENCESá : Reports First Quarter 2021 Financial Results (Form 8-K)
05/10PULSE BIOSCIENCESá : Management's Discussion and Analysis of Financial Condition..
More news
Financials (USD)
Sales 2021 1,20 M - -
Net income 2021 -83,3 M - -
Net Debt 2021 - - -
P/E ratio 2021 -5,55x
Yield 2021 -
Capitalization 459 M 459 M -
Capi. / Sales 2021 382x
Capi. / Sales 2022 10,4x
Nbr of Employees 95
Free-Float 47,8%
Duration : Period :
Pulse Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PULSE BIOSCIENCES, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 42,93 $
Last Close Price 17,34 $
Spread / Highest target 164%
Spread / Average Target 148%
Spread / Lowest Target 131%
EPS Revisions
Managers and Directors
Darrin R. Uecker President, Chief Executive Officer & Director
Sandra A. Gardiner CFO, Secretary, Treasurer & Executive VP-Finance
Robert William Duggan Chairman
Richard Nuccitelli Chief Science Officer
David Danitz Vice President-Engineering
Sector and Competitors